title: Dermatomyositis developing in the first trimester of pregnancy.
abstract: Dermatomyositis in pregnancy is rare. Pregnancy may be a precipitating factor at the onset or may develop during the course of dermatomyositis, which would exacerbate disease activity. In this study, we report a 22-year-old female patient who developed generalized skin rash and progressive muscle weakness in the twelfth week of pregnancy. She was diagnosed with dermatomyositis and underwent therapeutic abortion, due to the high fetal mortality rate of the disease when developed in the first trimester. Her symptoms improved with treatment of intravenous immunoglobulin and a high dose of corticosteroids.
authors: Department of Allergy and Rheumatology, Ajou University School of Medicine, San-5, Woncheon-dong, Paldal-gu, Suwon, 442-721, Korea.
authors: In Whee
authors: IW
authors: Park
authors: Yu Jin
authors: YJ
authors: Suh
authors: Jae Ho
authors: JH
authors: Han
authors: Yoo Seob
authors: YS
authors: Shin
authors: Jeong Hee
authors: JH
authors: Choi
authors: Hae Sim
authors: HS
authors: Park
authors: Chang Hee
authors: CH
authors: Suh
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003882:Dermatomyositis / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D011239:Prednisolone / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications; D011261:Pregnancy Trimester, First; D012867:Skin / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D016756:Immunoglobulins, Intravenous; D011239:Prednisolone